Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice

Abstract

Objective Amyloid positron emission tomography (PET) plays a vital role in the in vivo detection of β-amyloid accumulation in Alzheimer's disease. Increasingly, trainees and infrequent readers are relying on semiquantitative analyses to support clinical diagnostic efforts. Our objective was to determine if the visual assessment of amyloid PET may be facilitated by relying on semiquantitative analysis.

Methods We conducted a retrospective review of [¹⁸F]-florbetaben PET/computed tomographies (CTs) from 2016 to 2018. Visual interpretation to determine Aβ+ status was conducted by two readers blinded to each other's interpretation. Scans were then post-processed utilizing the MIMneuro software, which generated regional-based semiquantitative Z-scores indicating cortical Aβ-burden.

Results Of 167 [¹⁸F]-florbetaben PET/CTs, 92/167 (reader-1) and 101/167 (reader-2) were positive for amyloid deposition (agreement = 92.2%, κ = 0.84). Additional nine scans were identified as possible Aβ-positive based solely on semiquantitative analyses. Largest semiquantitative differences were identified in the left frontal lobe (Z = 7.74 in Aβ + ; 0.50 in Aβ − ). All unilateral regions showed large statistically significant differences in Aβ-burden (P ≤ 2.08E-28). Semiquantitative scores were highly sensitive to Aβ+ status and accurate in their ability to identify amyloid positivity, defined as a positive scan by both readers (AUC ≥ 0.90 [0.79–1.00]). Spread analyses suggested that amyloid deposition was most severe in the left posterior cingulate gyrus. The largest differences between Aβ +/Aβ− were in the left frontal lobe. Analyses using region-specific cutoffs indicated that the presence of amyloid in the temporal and anterior cingulate cortex, while exhibiting relatively low Z-scores, was most common.

Conclusion Visual assessment and semiquantitative analysis provide highly congruent results, thereby enhancing reader confidence and improving scan interpretation. This is particularly relevant, given recent advances in amyloid-targeting disease-modifying therapeutics.

Keywords

β-amyloid - ¹⁸F-florbetaben - PET/CT - brain PET - Alzheimer's disease

Publication History

Article published online:
28 October 2022

• References

• 1 Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA 2019; 322 (16) 1589-1599 DOI: 10.1001/jama.2019.4782.
• 2 2021 Alzheimer's disease facts and figures. Alzheimers Dement 2021; 17 (03) 327-406 DOI: 10.1002/alz.12328.
• 3 Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80 (19) 1778-1783
• 4 Alzheimer A. Ueber eine eigenartige erkrankung der hirnrinde. Z Gesamte Neurol Psychiatr 1907; 18: 177-179
• 5 Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med 2010; 77 (01) 32-42 DOI: 10.1002/msj.20157.
• 6 Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1 (01) a006189 DOI: 10.1101/cshperspect.a006189.
• 7 Thal DR, Rüb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58 (12) 1791-1800 DOI: 10.1212/wnl.58.12.1791.
• 8 Hanseeuw BJ, Betensky RA, Jacobs HIL. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol 2019; 76 (08) 915-924 DOI: 10.1001/jamaneurol.2019.1424. Erratum in: JAMA Neurol. 2019 Aug 1;76(8):986. PMID: 31157827; PMCID: PMC6547132
• 9 Cho H, Lee HS, Choi JY. et al. Predicted sequence of cortical tau and amyloid-β deposition in Alzheimer disease spectrum. Neurobiol Aging 2018; 68: 76-84 DOI: 10.1016/j.neurobiolaging.2018.04.007.
• 10 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020; 6 (01) e12050 DOI: 10.1002/trc2.12050.. PMID: 32695874; PMCID: PMC7364858
• 11 Jack Jr CR, Bennett DA, Blennow K. et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016; 87 (05) 539-547 DOI: 10.1212/WNL.0000000000002923.
• 12 Jack Jr CR, Bennett DA, Blennow K. et al; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14 (04) 535-562
• 13 Knopman DS, Haeberlein SB, Carrillo MC. et al. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: perspectives from the research roundtable. Alzheimers Dement 2018; 14 (04) 563-575 DOI: 10.1016/j.jalz.2018.03.002.
• 14 FDA Grants Accelerated Approval for Alzheimer's Drug. Accessed: July 25, 2021, at: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
• 15 Becker GA, Ichise M, Barthel H. et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013; 54 (05) 723-731
• 16 Ishii K, Yamada T, Hanaoka K. et al. Regional gray matter-dedicated SUVR with 3D-MRI detects positive amyloid deposits in equivocal amyloid PET images. Ann Nucl Med 2020; 34 (11) 856-863 DOI: 10.1007/s12149-020-01513-3.
• 17 Akamatsu G, Ikari Y, Ohnishi A. et al; Japanese Alzheimer's Disease Neuroimaging Initiative. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. EJNMMI Res 2019; 9 (01) 91 DOI: 10.1186/s13550-019-0561-2.
• 18 Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study. Accessed July 25, 2021, at: https://clinicaltrials.gov/ct2/show/NCT02420756
• 19 Johnson KA, Minoshima S, Bohnen NI. et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Taskforce, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013; 9 (01) e-1-e-16 DOI: 10.1016/j.jalz.2013.01.002.
• 20 Minoshima S, Drzezga AE, Barthel H. et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 2016; 57 (08) 1316-1322 DOI: 10.2967/jnumed.116.174615.
• 21 Murray ME, Lowe VJ, Graff-Radford NR. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015; 138 (Pt 5): 1370-1381 DOI: 10.1093/brain/awv050.
• 22 Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med 2014; 55 (12) 2003-2011 DOI: 10.2967/jnumed.114.141416.
• 23 Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BNM. Molecular Imaging Approaches in Dementia. Radiology 2021; 298 (03) 517-530 DOI: 10.1148/radiol.2020200028.
• 24 Landau SM, Thomas BA, Thurfjell L. et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014; 41 (07) 1398-1407 DOI: 10.1007/s00259-014-2753-3.
• 25 Landau SM, Breault C, Joshi AD. et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013; 54 (01) 70-77 DOI: 10.2967/jnumed.112.109009.
• 26 Villemagne VL, Mulligan RS, Pejoska S. et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39 (06) 983-989 DOI: 10.1007/s00259-012-2088-x.
• 27 Lundeen TF, Seibyl JP, Covington MF, Eshghi N, Kuo PH. Signs and artifacts in amyloid PET. Radiographics 2018; 38 (07) 2123-2133
• 28 Clark CM, Schneider JA, Bedell BJ. et al; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305 (03) 275-283
• 29 Barthel H, Luthardt J, Becker G. et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011; 38 (09) 1702-1714 DOI: 10.1007/s00259-011-1821-1.
• 30 Rabinovici GD, Gatsonis C, Apgar C. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321 (13) 1286-1294 DOI: 10.1001/jama.2019.2000.
• 31 Yamane T, Ishii K, Sakata M. et al; J-ADNI Study Group. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of ¹¹C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging 2017; 44 (05) 850-857 DOI: 10.1007/s00259-016-3591-2.
• 32 Hosokawa C, Ishii K, Hyodo T. et al. Investigation of (11)C-PiB equivocal PET findings. Ann Nucl Med 2015; 29 (02) 164-169 DOI: 10.1007/s12149-014-0924-8.
• 33 Rullmann M, Dukart J, Hoffmann KT. et al. Partial-volume effect correction improves quantitative analysis of 18F-florbetaben β-amyloid PET scans. J Nucl Med 2016; 57 (02) 198-203 DOI: 10.2967/jnumed.115.161893.
• 34 Sarikaya I, Kamel WA, Ateyah KK, Essa NB, AlTailji S, Sarikaya A. Visual versus semiquantitative analysis of ¹⁸F- fluorodeoxyglucose-positron emission tomography brain images in patients with dementia. World J Nucl Med 2021; 20 (01) 82-89 DOI: 10.4103/wjnm.WJNM_53_18.
• 35 Sarikaya I, Sarikaya A, Elgazzar AH. Current status of ¹⁸F-FDG PET brain imaging in patients with dementia. J Nucl Med Technol 2018; 46 (04) 362-367 DOI: 10.2967/jnmt.118.210237.
• 36 Klunk WE, Koeppe RA, Price JC. et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015; 11 (01) 1-15.e1, 4 DOI: 10.1016/j.jalz.2014.07.003.
• 37 Rowe CC, Doré V, Jones G. et al. ¹⁸F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging 2017; 44 (12) 2053-2059 DOI: 10.1007/s00259-017-3749-6.